Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Dispose of 11,379 Treasury Shares Worth KRW 1.65B for Stock Option Settlements

Posted on January 21, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Dispose of 11,379 Treasury Shares Worth KRW 1.65B for Stock Option Settlements

Fact Source: Financial Supervisory Service DART / 2026-01-21

Disclosure Type: Decision on Disposal of Treasury Shares

💡 3-Second Summary

Celltrion has decided to deliver 11,379 of its treasury common shares (valued at approximately KRW 1.65 billion) to settle stock option exercises by 10 of its executives and employees.

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • Shares to be Disposed: 11,379 Registered Common Shares
  • Disposal Price per Share: KRW 144,840
    • Calculated as a weighted average of strike prices based on the number of shares exercised per tranche.
  • Total Estimated Disposal Amount: KRW 1,648,139,691 (Approx. KRW 1.65B)
  • Scheduled Disposal Period: January 21, 2026 (Single-day settlement)
  • Purpose of Disposal: Delivery of treasury shares following the exercise of stock options
  • Disposal Method: Others (Direct transfer from Celltrion’s treasury account to individual securities accounts of the exercisers; no brokerage firm is involved).
  • Counterparty: 10 company executives and employees
  • Date of Disposal Decision: January 21, 2026 (Based on the internal draft date)
    • Pursuant to Article 176-2 of the Enforcement Decree of the Financial Investment Services and Capital Markets Act, this decision does not require a formal board of directors resolution.

[Stock Option Execution Details]

  • 1st Tranche (Grant Date 2022.03.25): 10,366 shares / Strike Price KRW 146,601 / Total Amount KRW 1,519,665,966
  • 2nd Tranche (Grant Date 2022.03.25): 1,013 shares / Strike Price KRW 126,825 / Total Amount KRW 128,473,725
    • The initial grant date was March 25, 2022, and the exercise period spans from March 25, 2025, to March 24, 2032.
    • The closing stock price on the day prior to the disposal decision was KRW 207,000.

[Treasury Share Holdings Prior to Disposal (As of January 21, 2026)]

  • Shares Acquired within Distributable Profit Limit: 7,165,466 shares (3.1%)
  • Shares Acquired via Other Methods: 5,182,379 shares (2.2%)
  • Total Treasury Shares Held: 12,347,845 shares (5.3%)

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This treasury share disposal disclosure outlines a routine operational transfer rather than a market-destabilizing event. Since the execution utilizes pre-existing treasury stock instead of issuing new shares, the transaction does not expand the total outstanding share capital of Celltrion. Additionally, because the delivery is completed via direct accounting transfers to the individual securities accounts of the 10 executives and employees—bypassing direct open-market sales or block-deal networks—the near-term open-market liquidity impact is limited.

From a financial architecture standpoint, the total disposal volume of 11,379 shares mathematically accounts for 0.00% of Celltrion’s total issued share capital, indicating that the dilution of equity ownership for existing shareholders is negligible. While the weighted average exercise price of KRW 144,840 is discounted compared to the previous day’s closing price of KRW 207,000, it represents a mechanical settlement of previously granted options. Consequently, investors could prudently interpret this development as a standard corporate compensation action rather than a strategic divestment or capital deterioration, signaling a potential impact of neutral fundamental friction.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s latest share transfer represents a standard corporate housekeeping action to satisfy outstanding stock options for its internal human assets. Because the company is delivering pre-existing treasury blocks rather than diluting the capital structure through new share creation, the structural integrity of the stock’s per-share value remains intact. While a minor portion of these shares could eventually be liquidated on the open market due to the favorable discount rate relative to the trading price, the microscopic scale of the block means any resulting market friction will be completely absorbed by the stock’s robust daily trading depth. Market participants should view this as a neutral administrative execution.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Samsung Biologics (207940) Reports Q4 2025 Preliminary Revenue of KRW 1.29T and Operating Profit of KRW 528.3B… Up 67.8% YoY
Next Post: [Disclosure] Samsung Biologics (207940) Designated as Short-Selling Overheated Stock… Short-Selling Banned on January 23 for 1 Day

Related Posts

[Disclosure] Samsung Biologics (207940) Extends LOI Period and Confidentiality Deadline to Dec 31 for KRW 154.1B CMO Deal Disclosures
[Disclosure] Samsung Biologics (207940) Signs KRW 178B Contract Manufacturing Deal with European Pharma Co. Disclosures
[Disclosure] Samsung Biologics (207940) Extends Non-Disclosure Deadline to 2033 for CMO Contract Disclosures
[Disclosure] Samsung Biologics (207940) Submits Audit Report… Consolidated Operating Profit Surpasses KRW 2T with ‘Unqualified’ Opinion Disclosures
[Disclosure] Samsung Biologics (207940) to Face Trading Suspension Starting October 30 Due to Corporate Split Registrations Disclosures
[Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in Europe Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme